BIIB Biogen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIIB

Price (delayed)

$197.19

Market cap

$29.11B

P/E Ratio

21.09

Dividend/share

N/A

EPS

$9.35

Enterprise value

$32.29B

?
Relative Growth: Rel. Growth: 34
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 54
Relative Profitability: Rel. Profitability: 68

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. ...

Highlights
The company's quick ratio has surged by 133% YoY and by 19% QoQ
The equity has grown by 10% YoY and by 2.2% from the previous quarter
The EPS has contracted by 8% YoY but it has grown by 6% from the previous quarter
Biogen's net income has decreased by 7% YoY but it has increased by 6% QoQ
The P/E is 33% above the last 4 quarters average of 16.1 and 10% above the 5-year quarterly average of 19.5
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.biogen.com/
Peers: AMGN GILD PFE ABBV

Key stats

What are the main financial stats of BIIB

BIIB stock price

How has the Biogen stock price performed over time
Intraday
-1.26%
1 week
0.81%
1 month
1.77%
1 year
58.06%
YTD
12.05%
QTD
7.56%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$9.94B
Gross profit
$7.5B
Operating income
$1.62B
Net income
$1.37B
Gross margin
75.5%
Net margin
13.8%
Biogen's net margin has decreased by 9% YoY but it has increased by 5% from the previous quarter
Biogen's operating margin has decreased by 9% YoY but it has increased by 3.8% from the previous quarter
BIIB's operating income is down by 7% year-on-year but it is up by 4.3% since the previous quarter
Biogen's net income has decreased by 7% YoY but it has increased by 6% QoQ

Price vs fundamentals

How does BIIB's price correlate with its fundamentals

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
BIIB P/E details
P/E
21.09
P/B
1.55
P/S
2.92
EV/EBIT
19.9
EV/EBITDA
13.28
EV/Sales
3.25
The P/E is 33% above the last 4 quarters average of 16.1 and 10% above the 5-year quarterly average of 19.5
The EPS has contracted by 8% YoY but it has grown by 6% from the previous quarter
BIIB's price to book (P/B) is 35% lower than its 5-year quarterly average of 2.4 but 21% higher than its last 4 quarters average of 1.3
The equity has grown by 10% YoY and by 2.2% from the previous quarter
The stock's price to sales (P/S) is 29% more than its last 4 quarters average of 2.3 but 8% less than its 5-year quarterly average of 3.2

Efficiency

How efficient is Biogen business performance
The ROIC has contracted by 20% YoY and by 2.4% from the previous quarter
The ROE has contracted by 17% YoY but it has grown by 2.7% from the previous quarter
Biogen's return on assets has decreased by 11% YoY but it has increased by 4.4% QoQ
The ROS has contracted by 9% YoY but it has grown by 3.8% from the previous quarter

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 172% more than the total liabilities
The company's quick ratio has surged by 133% YoY and by 19% QoQ
The current ratio has soared by 113% YoY and by 14% from the previous quarter
Biogen's debt is 65% less than its equity
The equity has grown by 10% YoY and by 2.2% from the previous quarter
The debt to equity has decreased by 10% YoY and by 2.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.